Therapy: The second time as farce: rosiglitazone and the regulators

EAM Gale

Research output: Contribution to journalArticle (Academic Journal)peer-review

8 Citations (Scopus)

Abstract

Rosiglitazone is the second of the marketed thiazolidinediones to fall from grace, and its demise bears an uncanny resemblance to the earlier downfall of troglitazone. Both narratives demonstrate the inadequacy of a regulatory system that is mandated to place a higher value on commercial secrecy than on patient safety.
Translated title of the contributionTherapy: The second time as farce: rosiglitazone and the regulators
Original languageEnglish
Pages (from-to)5 - 6
Number of pages2
JournalNature Reviews Endocrinology
Volume7(1)
DOIs
Publication statusPublished - Jan 2011

Fingerprint Dive into the research topics of 'Therapy: The second time as farce: rosiglitazone and the regulators'. Together they form a unique fingerprint.

Cite this